Developing Novel Preclinical Models For Neurodevelopmental Disorders - From Bedside To Bench
Funder
National Health and Medical Research Council
Funding Amount
$1,714,215.00
Summary
I will use the knowledge gained from our studies of progressive brain structural and cognitive changes in neuropsychiatric disorders (esp. psychosis and schizophrenia), to develop novel animal models of brain development, identify the impact of insults (e.g. viral infection) at different stages of development, and identify new treatments and optimal timing of interventions to prevent or ameliorate brain changes and cognitive deficits.
Leveraging Record Linkage For Single-indication Medications To Boost Recruitment In Psychiatric And Pharmaco- Genetics
Funder
National Health and Medical Research Council
Funding Amount
$1,840,595.00
Summary
Genome-wide association studies (GWAS) have shown that psychiatric disorders are highly polygenic and that increasing the power of these analyses by increasing the number of participants does lead to the identification of new treatment targets and biomarkers. We seek funding to greatly boost the power of GWAS for Schizophrenia and Bipolar Disorder by using prescription records to recruit individuals who have been prescribed medications that are only used to treat these conditions.
Schizophrenia: Prevention And Treatment Of Atypical Antipsychotic Drug-induced Obesity
Funder
National Health and Medical Research Council
Funding Amount
$413,862.00
Summary
Atypical antipsychotic drugs such as olanzapine, clozapine and risperidone are commonly used to treat mental illness. While these drugs are effective, their side effects of obesity and metabolic disorders are a major hurdle leading to a serious lack of compliance in taking medication. This project will define the mechanism leading to these side effects and will help to identify pharmaceutical targets for the better treatment of mentally ill patients.
A Prospective Study Investigating Implications Of Bioactive Lipids For Diagnosis And Treatment Of Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$324,480.00
Summary
This study will investigate the role of fatty acids (lipids) in schizophrenia. Studies in blood cells and in the brains of patients with schizophrenia have shown that these lipids and related products are altered in schizophrenia. We are now able to measure separate lipid metabolites in the living human brain using a technique called magnetic resonance spectroscopy. Until recently it was only possible to assess lipid metabolites as a group, limiting interpretation. Thanks to a newly available im ....This study will investigate the role of fatty acids (lipids) in schizophrenia. Studies in blood cells and in the brains of patients with schizophrenia have shown that these lipids and related products are altered in schizophrenia. We are now able to measure separate lipid metabolites in the living human brain using a technique called magnetic resonance spectroscopy. Until recently it was only possible to assess lipid metabolites as a group, limiting interpretation. Thanks to a newly available imaging system at the Brain Imaging Research Institute and a new analysis technique, we will be able to measure single lipid metabolites in the living human brain. Simultaneously we will also measure lipids and related enzymes in red blood cells that are responsible for the regulation of these lipids. Preliminary data has shown that there is a strong correlation between these two measures. Furthermore we will investigate the genes that are responsible for the production of these enzymes. By repeating the same tests after 12 weeks we hope to understand how the newer antipsychotic drugs act. Two easy clinical tests (a skin and breath test) will help us to implement the findings in daily clinical practice (diagnostic markers for patients at risk) . With such a multi-level approach we hope to contribute to a new understanding of the origins of schizophrenia going beyond the traditional concepts. The findings might also have direct implications for treatment. Preliminary results are very promising but also contradictory. Therefore it is even more important to carefully investigate the role of these lipids in schizophrenia.Read moreRead less
Studies On The Expression Of Muscarinic Receptors: Implications For The Pathology Of Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$498,791.00
Summary
Schizophrenia is a severe psychiatric disorder that affects approximately 1% of the population. This project will help define changes in the molecules in the brain of subjects with schizophrenia which are likely to be involved in two symptoms of the disorder, the psychoses and cognitive deficits. Understanding the cause of the cognitive deficits of schizophrenia is a high priority because they are the most disabilitating symptom of the disorder and do not respond to current drug treatments.
Selective Estrogen Receptor Modulators (SERMs) A Potential Treatment For Psychotic Symptoms Of Schizophrenia?
Funder
National Health and Medical Research Council
Funding Amount
$701,276.00
Summary
Schizophrenia is a serious disease with increasing social and economic costs. We need new treatments to improve the life and functioning of people with schizophrenia. We have published studies showing that estrogen is potentially a new treatment for schizophrenia. New brain estrogens called Selective Estrogen Receptor Modulators have fewer side-effects than standard estrogen. We will conduct a controlled clinical trial of a SERM in 180 postmenopausal women with schizophrenia.
N-Acetyl Cysteine In Schizophrenia Resistant To Clozapine: A Double-Blind Randomised Placebo-Controlled Trial Targeting Negative Symptoms
Funder
National Health and Medical Research Council
Funding Amount
$981,789.00
Summary
Many patients with schizophrenia remain treatment resistant even after “last resort” medications like clozapine. This proposal will conduct a novel multi-site randomised placebo controlled trial of adjunctive N-acetyl cysteine in patients with clozapine resistant schizophrenia. Treatment efficacy will be examined at 8, 26 and 52 weeks.
A Comparison Of An Integrated Psychological Intervention With 'befriending' In First-presentation Psychosis
Funder
National Health and Medical Research Council
Funding Amount
$356,113.00
Summary
The project aims to test the efficacy of two treatments to determine whether 'integrated' psychological treatment leads to better outcomes for those individuals presenting for treatment for the first time. Neuroleptic medication is the main treatment for the positive symptoms (i.e., delusions, hallucinations and thought disorder) which typify the psychoses, including schizophrenia. Yet, there are reasons why other approaches should be investigated. Firstly, not all patients respond to medication ....The project aims to test the efficacy of two treatments to determine whether 'integrated' psychological treatment leads to better outcomes for those individuals presenting for treatment for the first time. Neuroleptic medication is the main treatment for the positive symptoms (i.e., delusions, hallucinations and thought disorder) which typify the psychoses, including schizophrenia. Yet, there are reasons why other approaches should be investigated. Firstly, not all patients respond to medications. Secondly, medication may not totally alleviate the positive symptoms, and thirdly, other aspects of the condition are not helped to any extent by medication. These aspects include negative symptoms (e.g., lack of motivation and asociality), depression, social anxiety and functioning in the various life domains, e.g., school, work and socialization. In the last 15 years a viable psychological treatment known as cognitive-behavioural therapy (CBT) has emerged. This appears to be effective in the treatment of hallucinations and delusions and has an effect over and above that produced by medication. However, such treatments have not yet been applied to treating those symptoms in first presentation psychotic patients when they are in the acute stage of their illness. It is important to determine whether CBT produces positive effects in this group and whether used in conjunction with medication it can produce greater and more rapid reductions in the level and severity of positive symptoms. Whilst CBT is expected to produce positive changes in delusions and hallucinations, the applicants believe this needs to be integrated with CBT interevention focussed on other aspects of a patient's presentation, such as negative and depressive symptoms, and also on improving functioning in various life domains.Read moreRead less